Targeted Disease(s):
Asthma
Purpose of Study:
PrecISE is a clinical study sponsored by the U.S. National Heart, Lung, and Blood Institute (NHLBI) to investigate several treatments for severe asthma. PrecISE will enroll 800 adults and teenagers (ages 12 years and older) with severe asthma who have symptoms that are not well-controlled on high dose of inhaled corticosteroids including those who have frequent asthma attacks. Each person who agrees to enroll in the PrecISE study will receive several treatments for research purposes based on their type of severe asthma.The goal of PrecISE is to understand how to treat different types of severe asthma, by using precision medicine. Precision medicine is an approach that targets treatments to defined subgroups of patients who share similar characteristics, for example, patients with a certain genetic variation or patients with high number of blood eosinophils. Researchers from over 30 locations across the US, as well as sites in Canada and the United Kingdom, are involved in PrecISE.
Study Dates:
Ongoing - June 1, 2023
Type of Study:
Pre-Market
Study Design:
Controlled Design
Study Location:
Nationwide
Lead Institution:
University of North Carolina Chapel Hill
Funding Source:
NIH/NHLBI
Sponsors:
NIH/NHLBI
Contact:
See names for each site at: https://preciseasthma.org/preciseweb/Study-Sites-By-Location
ClinicalTrails.gov Identifier:
NCT04129931
